Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
- A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.
| MarketCap | 229.7M |
|---|---|
| PE Ratio | 5.2 |
| PEG Ratio | |
| P/B | 3.0 |
| P/S (ttm) | 2.5 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 17% |
| Held by Institutions % | 33% |
| 1 Day Vol Adjusted Return | -0.0 |
| 1 Month Vol Adjusted Return | 3.5 |
| 3 Month Vol Adjusted Return | 11.7 |
| 6 Month Vol Adjusted Return | -0.5 |
| 20 Days SMA Price ZScore | 1.8 |
| 50 Days SMA Price ZScore | 2.1 |
| 12 -26 Days PPO | 4.9 |
| 1 Month Average Short Volume Ratio | 45.3 |
| 1 Day Volume Change ZScore | -0.3 |
| 1 Month Daily Vol | 3.1 |
Stock news
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be attending and speaking at the Yale School of Public Health SalivaDirect™ Conference held July 28-29 in Chicago, Il.
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC.
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth to showcase its existing and upcoming suite of diagnostics products and technology applications at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo, held July 24-28 at the McCormick Place Convention Center in Chicago, IL, in addition to providing an update for
Shares of Co-Diagnostics (NASDAQ: CODX) are up by more than 5% as of 9:52 a.m. ET on Monday after the company reported that it sent the first shipment of its new molecular diagnostic test for monkeypox to one of its customers outside the U.S. The initial research and development (R&D) work for the test wrapped up on May 26, so going from concept design to shipping the product only took a little more than a month. Co-Diagnostics is known for its molecular coronavirus tests, thanks to which its ...
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has shipped testing reagents for monkeypox virus currently exhibiting a multi-country outbreak to one of its international distributors.
Shares of Co-Diagnostics (NASDAQ: CODX) were running 4.6% higher Tuesday morning as of 10:30 a.m. ET on no company-specific news, though it may be getting a boost from an update from the World Health Organization (WHO). The World Health Organization reported this morning there are 5,322 laboratory-confirmed cases of monkeypox. Co-Diagnostics CEO Dwight Egan has said the healthcare company was founded to make low-cost, high-quality tests available wherever they're needed, and it looks "forward ...
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting this week at the 29th International Biodetection Technologies Conference, held virtually June 28-29, 2022.
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.